Bioiberica increases product sales on international markets
Bioiberica has followed a vertical integration strategy in the last three years towards the development and sale of finished products. All products undergo scientific and clinical development and have their own marketing strategy to support sales in each country.
Results have been consolidated over the years and the company's products in the Joint Care line are now being marketed in Italy, Germany, Belgium, the Netherlands, Greece, Turkey and Slovenia. Further launches in Europe and Asia are planned in 2010. Bioiberica has also reached an important agreement with Merck KGaA for product distribution in several countries.
One of the company's aims is to expand its Joint Care portfolio to other therapeutic areas such as immunology: In 2009 Bioiberica launched Inmunactive in Spain, its first product designed to preserve and improve compromised immune systems. In 2010 the product will be launched on international markets.
Related News
On a planet where natural resources are limited and there is increasing concern for the environment, the circular economy has emerged as an innovative and sustainable solution.
We participated in CPHI 2023 in Barcelona, where we showcased our leadership in scientific research, sustainable development and strategic partnerships for a more resilient future with our portfolio of Active Pharmaceutical and Nutraceutical Ingredients.
They've set up Biovall Heparin Science, a joint pharmaceutical innovation project with an investment of 25 million euros and 20 skilled jobs